| Description | LGD-4033 is a novel nonsteroidal, oral SARM that binds to androgen receptor with high affinity (Ki of 1 nM) and selectivity.IC50 value: 1 nM (Ki, for androgen receptor) Target: androgen receptorin vitro: LGD-4033, a novel nonsteroidal oral, selective androgen receptor modulator, binds androgen receptor with high affinity and selectivity.in vivo: LGD-4033 has demonstrated anabolic activity in the muscle, anti-resorptive and anabolic activity in bone, and robust selectivity for muscle versus prostate In animal models. LGD-4033 is well tolerated, has a long elimination half-life and dose-proportional accumulation upon multiple dosing. LGD-4033 is safe, has favorable pharmacokinetic profile, and increases lean body mass even during this short period without change in prostate-specific antigen. |
|---|
| Related Catalog | Signaling Pathways >> Others >> Androgen Receptor Research Areas >> Endocrinology |
|---|
| Solvent | In Vitro: 10 mM in DMSO |
|---|
| Solubility | 1 mM2.9564 mL14.7820 mL29.5639 mL5 mM0.5913 mL2.9564 mL5.9128 mL10 mM0.2956 mL1.4782 mL2.9564 mL |
|---|
| Storage | Powder-20°C3 years 4°C2 yearsIn solvent-80°C6 months -20°C1 month |
|---|
| Shipping | Room temperature in continental US; may vary elsewhere |
|---|
| SMILES | N#CC1=CC=C(N2[C@@H]([C@@H](O)C(F)(F)F)CCC2)C=C1C(F)(F)F |
|---|
| References | [1]. Basaria S,et al. The safety, pharmacokinetics, and effects of LGD-4033, a novel nonsteroidal oral, selective androgen receptor modulator, in healthy young men. J Gerontol A Biol Sci Med Sci. 2013 Jan;68(1):87-95. |
|---|
| Related Molecules | ARN-509 | Dehydroepiandrosterone | Flutamide | ODM-201 | Danazol | 3,3'-Diindolylmethane | AZD3514 | RAD140 | BMS-564929 | GLPG0492 | Cyproterone acetate | Lupeol | Andarine | MK-0773 | ORM-15341 |
|---|
China
